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ABSTRACT
Introduction: Colorectal cancer (CRC) arises from the cumulative effects of genetic and epigenetic alterations. Cur-
rent treatment of metastatic CRC relies on combination of chemotherapy and targeted therapies such as anti-EGFR 
therapies. The success of targeted therapies relies on the detection of actionable targets and predictive biomarkers 
of resistance. The study aims to determine mutations in common actionable targets and predictive biomarkers of re-
sistance to anti-EGFR therapies in Malaysian CRC patients.  Methods: Mutations in 10 CRC tissues were determined 
by next-generation sequencing with a panel of 7 cancer-related genes covering all exons in KRAS, BRAF, PIK3CA, 
PTEN, TP53, NRAS, and EGFR genes. Immunohistochemistry was used to determine mismatch repair (MMR) status. 
Results: Of the ten samples, 5 and 4 samples harboured two and one mutation, respectively and one had no mu-
tation. All were missense mutations and were in five genes, namely, KRAS, PIK3CA, TP53, BRAF, and EGFR. They 
were, G12D, G12V, G12A, G13D, and V14I in KRAS, E545K, K733R, and D1056N in PIK3CA, G199V, D259Y, 
and R282W in TP53, V600E in BRAF and G696R in EGFR. Deficient mismatch repair (dMMR) was detected in three 
samples, of which two had KRAS mutation. Conclusion: Mutations in KRAS codon 12 and 13, BRAF and PIK3CA 
which predict resistance to anti-EGFR therapies and three TP53 mutations were found. This is the first report of EGFR 
mutation in Malaysian CRC patients. It is predicted to be a pathogenic variant. dMMR,  one of the biomarkers for 
treatment with immune checkpoint inhibitor was also detected.
Keywords: Colorectal carcinoma (CRC), Next-generation sequencing (NGS), mismatch repair (MMR), Microsatellite 
Instability (MSI), mutation
Corresponding Author:  
Seow Heng Fong, PhD
Email: shf@upm.edu.my
Tel: +603-8947 2387
INTRODUCTION
Colorectal cancer (CRC) is a malignancy of the colon 
and rectum. It is a large group of heterogeneous diseases 
classified under the same category where the most 
common groups are sporadic CRC, familial CRC, and 
hereditary CRC. It is the third most common cancer 
in the world after lung and breast cancer (1). In 2012, 
nearly 1.4 million new cases of CRC were diagnosed 
around the world (1). In Malaysia, a total of 13,693 CRC 
cases was reported from 2007 to 2011 making CRC 
the most common cancer in male and the second most 
common cancer in female (2).
CRC arises from the cumulative effect of genetic 
and epigenetic alterations. Three distinct genomic 
instability pathways involved in CRC progression are 
chromosomal instability (CIN), microsatellite instability 
(MSI), and CpG island methylator phenotype pathways 
(CIMP)(3). CIN occurs in 70%-85% CRC cases which 
leads to gene deletions, duplications, and chromosomal 
rearrangements. MSI is caused by DNA mismatch repair 
(MMR) deficiency resulting in mutations at simple 
nucleotide repeat sequences. Approximately 15% 
sporadic CRCs are classified as MSI  (4). CIMP, on the 
other hand, is characterized by epigenetic instability, 
usually promoter hypermethylation (3).
Although many mutated genes have been reported in CRC, 
only fewer than 15 mutated genes are being considered 
as driver genes. These driver genes include tumour 
suppressor protein p53 (TP53), Kirsten rat sarcoma viral 
oncogene homolog (KRAS), adenomatous polyposis coli 
(APC), phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA), and F-Box And WD 
Repeat Domain Containing 7 (FBXW7) (5). The Cancer 
Genome Atlas Network has identified 32 recurrent 
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somatic mutations in CRC, with APC, TP53, KRAS, 
PIK3CA, FBXW7, SMAD4, TGBFBR2 (transforming 
growth factor–β receptor 2), and BRAF (proto-oncogene 
B-RAF) being amongst the most frequently mutated 
genes (6). In Malaysian CRCs, mutations in APC, KRAS, 
BRAF, PIK3CA, PTEN, and TP53 have been reported in 
separate studies (7)(8)(9)(10).
Next-generation sequencing (NGS) technology has 
enormous potential in cancer research. Development of 
cancer-specific gene panels has increased the potential 
of their utility in clinical diagnostics for selecting targeted 
therapies such as anti-EGFR therapies by detecting 
multiple mutations simultaneously thus increased the 
time and cost effectiveness of mutation detection test 
(11).
In this pilot study, next-generation sequencing was 
performed across a 7 cancer-related gene panel using 
10 CRC tissues. These 7 genes (KRAS, BRAF, PIK3CA, 
PTEN, TP53, NRAS, and EGFR) have been found to 
predict resistance to anti-EGFR therapies in metastatic 
CRC (12)(13)(14). These somatic variants are well-known 
and well-characterized hotspot mutations. They are also 
categorized as common actionable or clinically relevant 
somatic mutations. In clinical practice, patients with any 
known KRAS or NRAS mutation should not be treated 
with anti-EGFR therapies, while a BRAF inhibitor should 
be added in the anti-EGFR therapy for patients with 
BRAF mutation to overcome resistance. This pilot study 
attempted to predict the common actionable targets and 
those that are clinically relevant as predictive markers 
of resistance to anti-EGFR therapies in Malaysian CRC 
patients. The mutations identified will be valuable for 
designing new gene panels or assays for future mutation 
testing in Malaysia CRC population. This information will 
also be useful serving as negative predictive biomarker 
for anti-EGFR therapies in metastatic CRC patients.
MATERIALS AND METHODS
Tissue specimens and ethics statement
Formalin-fixed, paraffin-embedded (FFPE) tissues from 
10 CRC patients were obtained from the Hospital of Kuala 
Lumpur, Malaysia. The hematoxylin and eosin (H&E)-
stained tissue slides were reviewed by a pathologist to 
ensure sufficient tumour content. Clinicopathological 
and demographic data of each patient were collected 
from the medical records in the hospital. Ethical 
clearance from the National Medical Ethics Committee 
(NMRR-12-435-11565) was obtained for this study.
Next-generation sequencing
The FFPE tissues were sectioned at a thickness of 4 
µm using the Leica rotation microtome. Genomic 
DNA was extracted from a total of 20-µm-thick tissue 
sections using GeneAll FFPE extraction kit according 
to the manufacturer’s guide. The extracted DNA was 
quantified using the Qubit fluorometer. Libraries were 
generated from 10 ng of DNA using Ion AmpliSeq library 
preparation kit (Thermo Fisher Scientific) and multiple 
primer pairs that amplify all exonic regions of KRAS, 
BRAF, PIK3CA, PTEN, TP53, NRAS, and EGFR genes. 
Library quality control and quantification were done 
using the Agilent Bioanalyzer 2100 High Sensitivity 
DNA chips. The libraries were attached to the Ion Sphere 
particles and enriched using the Ion OneTouch 2 System 
with ES (Enrichment System) module (Thermo Fisher 
Scientific). Purified beads were loaded onto the Ion 
Torrent 316v2 chip. Sequencing was performed using 
the Ion Torrent PGM system for 200 cycles. Coverage 
depth of the sequencing was ~500x. Sequencing quality 
control was done on-board with Torrent Suite Software. 
Variants were called using Torrent Variant Caller. The 
variants were filtered by in-house, proprietary software, 
which compares the variants to those identified in 
COSMIC, UniProt, PolyPhen, and PubMed to produce 
a reduced, functional list of potentially deleterious 
variants and variants in oncogenes.
Immunohistochemical staining and evaluation
The 4-µm-thick paraffin-embedded tissue sections were 
dewaxed and hydrated before boiling in 10 mM sodium 
citrate buffer (pH6.0 for MSH6) or 10 mM Tris, 1 mM 
ethylenediamine tetraacetic acid (EDTA) buffer (pH 9.0 
for PMS2) for 20 minutes using microwave oven. The 
tissue sections were then incubated with 3% bovine 
serum albumin (BSA) for 1 hour after blocking the 
endogenous peroxidase with 3% hydrogen peroxide. 
Monoclonal primary antibodies, PMS2 (clone EP51, 
Dako Cytomation, Glostrup, Denmark, 1:100, 2 hours) 
or MSH6 (clone EP49, Dako Cytomation, Glostrup, 
Denmark, 1:200, 1 hour) was applied to tissue sections. 
The immunoreactivity detection was performed 
using the UltraVision Labeled Polymer (horseradish 
peroxidase) followed by the 3,3-diaminobenzidine 
(DAB) solution for colour development, according to the 
manufacturer’s instructions (Lab Vision; Thermo Fisher 
Scientific, Fremont, CA, USA). Tissue sections were 
then counterstained with hematoxylin, dehydrated, 
and mounted. Negative controls were prepared by 
substituting the primary antibodies with Tris-buffered 
saline (TBS). The staining of MSH6 and PMS2 was 
considered positive when more than 10% of nuclear 
staining was observed. MMR was considered deficient 
when either MSH6, PMS2 or both staining in the tumour 
tissue was negative.
RESULTS
The demographic background characteristics of the 
patients are presented in Table I. The overall median 
age was 69 years old. Sixty percent of the patients were 
male and 40% were female. There were four patients 
in Dukes’ B and three patients in Dukes’ C stage. The 
majority of tumours were moderately differentiated 
(seven out of ten) and located at the right side of the 
colon (eight out of ten) (Table I). 
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A total of 2.6 million reads for 10 CRC DNA samples 
with 66% of loading density were obtained from the 
result. After eliminating loading, enrichment and 
clonality factors, a final of 80% of the library reads were 
used to perform bioinformatics analysis. Twenty percent 
of the reads were filtered due to test fragments, adapter 
dimer and low quality. All CRC DNA samples had more 
than 95% of total bases equal or above Phred Score 20 
(>Q20) which is the default setting for data analysis with 
the Ion Torrent PGM instrument. Only reads with bases 
more than Q20 were selected to perform downstream 
analysis, where 99.2% of these reads were aligned to 
reference Human Genome 19 (Hg 19). Samples 006, 
007 and 008 had significantly lower numbers of reads 
compared to other samples. 
A total of 13 mutations were detected in five genes, 
namely, KRAS, PIK3CA, TP53, BRAF, and EGFR. All 
mutations detected in this study were missense mutations. 
Among the nine samples detected with mutations, five 
samples harboured two mutations while four samples 
harboured one mutation. Three genes, KRAS, PIK3CA 
and TP53 were altered in at least three samples. The 
most common mutation was KRAS mutation, where 
three samples harboured mutations at codon 12, two 
samples at codon 13 and one sample had a mutation at 
codon 14. These mutations were G12D, G12V, G12A, 
G13D, and V14I. Three PIK3CA mutations were detected 
in this study, resulting in amino acid changes, E545K, 
K733R, and D1056N. In TP53, the detected mutations 
were G199V, D259Y and R282W. In this study, BRAF 
mutation (V600E) and EGFR mutation (G696R) were 
detected in only one sample each. No mutations were 
detected in one of the samples (Table II). 
In this study, positive immunoreactivity for MSH6 
protein was detected in nine samples (90%) (Figure 1) 
Table I: Clinicopathological features of CRC patients
Sample 
ID
Gen-
der
Age
Histological 
Grade
Stage
Tumour 
siteDukes’
TNM 
staging
001 F 75
Moderately 
Differentiated
C T3N2Mx
Right-
sided
002 M 68
Moderately 
Differentiated
NA1 T4N1M1
Right-
sided
003 M 64
Moderately 
Differentiated
C T3N1M0
Right-
sided
004 M 76
Moderately 
Differentiated
B T3N0Mx
Left-
sided
005 M 59
Moderately 
Differentiated
B T3N0Mx
Right-
sided
006 F 69
Moderately 
Differentiated
NA1 T3N0M0
Left-
sided
007 F 71
Well Differ-
entiated
B T3N0Mx
Right-
sided
008 M 69 NA NA1 T3N0M
Right-
sided
009 F 60
Moderately 
Differentiated
B T4N0Mx
Right-
sided
010 M 82 NA C2 T4N2M
Right-
sided
1 NA- Not Available
Table II Type of mutations in Gene, Base and Amino Acid change 
and MSI status
Sample 
ID.
Gene
Type of 
mutation
Chromosome : 
Position
Base 
change
Amino 
Acid 
change
MSI 
status
001
KRAS MISSENSE 12 : 25398284 C -> T G12D
No
PIK3CA MISSENSE 3 : 178936091 G -> A E545K
002
BRAF MISSENSE 7 : 140453136 A -> T V600E
No
TP53 MISSENSE 17 : 7577506 C -> A D259Y
003 KRAS MISSENSE 12 : 25398284 C -> G G12A No
004
EGFR MISSENSE 7 : 55241638 G -> A G696R
No
PIK3CA MISSENSE 3 : 178952111 G -> A D1056N
005 KRAS MISSENSE 12 : 25398279 C -> T V14I Yes
006 KRAS MISSENSE 12 : 25398284 C -> A G12V No
007
PIK3CA MISSENSE 3 : 178941879 A -> G K733R
No
TP53 MISSENSE 17 : 7578253 C -> A G199V
008 No mutation detected Yes
009
KRAS MISSENSE 12: 25398281 C -> T G13D
No
TP53 MISSENSE 17 : 7577094 G -> A R282W
010 KRAS MISSENSE 12 : 25398281 C -> T G13D Yes
Figure 1:  Positive staining of MSH6 in nuclei of tumour tissue 
(100x magnification)
and not detected in one samples (10%) (Figure 2). For 
PMS2 protein, positive immunoreactivity was detected 
in eight samples (80%) (Figure 3) and not detected in 
two samples (20%) (Figure 4). None of the samples 
exhibited negative immunoreactivity to both MSH6 and 
PMS2. Three samples with PMS2 or MSH6 negative 
immunoreactivity were considered MSI positive. Of 
these 3 samples, two had a KRAS mutation, whereas the 
remaining sample did not harbour any mutations in the 
seven genes tested (Table II).
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technology takes a step closer to “precision medicine” 
where the treatment provided is tailored to the genomic 
information of the patient. The genomic profile of a 
population is the foundation of developing a gene panel. 
This study attempts to predict the common targetable 
mutations and predictive biomarker of resistance to anti-
EGFR therapies in Malaysian CRC patients.
In this study, mutations in seven genes in CRC was 
screened using NGS with a 7-cancer gene panel. These 
7 genes are commonly altered in CRC population and 
have been reported to predict resistance to anti-EGFR 
therapies in metastatic CRC patients. Overall, 90% 
(9/10) of the samples harboured at least one mutation. 
The most frequent mutation identified in this study is 
the KRAS gene. Consistent with the previous studies in 
Malaysia (8), four hotspot mutations of KRAS (G12A, 
G12D, G12V, and G13D) was found in 6 CRC samples. 
These mutations localized in the GTP nucleotide binding 
domain impair GTPase activity rendering mutant KRAS 
protein persistently active, thereby activating the 
downstream signaling pathways. Karapetis et al. and 
Amado et al., separately reported that CRC patients with 
these KRAS mutations do not benefit from cetuximab 
and panitumumab (15)(16). Our study also found a 
mutant variant, KRAS V14I in the GTP-binding region. 
This mutation has a low frequency in CRC but has been 
reported to reduce KRAS GTPase activity leading to its 
constitutive activation and upregulation of downstream 
ERK signaling (17).
The majority of KRAS mutations occur at codons 12, 
13, and 61 resulting in constitutive activation of KRAS 
protein (18), which promotes proliferation and inhibits 
apoptosis of cancer cells (19). KRAS mutation was found 
in 35%-45% of CRCs (20). The mutation status of KRAS 
is a predictive biomarker for anti-EGFR therapy in CRC. 
Metastatic CRCs (mCRC) with mutant KRAS are resistant 
to cetuximab and panitumumab (approved anti-EGFR 
drugs) (21)(22). In the first-line treatment of mCRC, 
the addition of cetuximab to FOLFOX [folinic acid 
(leucovorin), fluorouracil (5-FU), oxaliplatin]/FOLFIRI 
[folinic acid (leucovorin), fluorouracil (5-FU), irinotecan 
(Camptosar)] does not improve the progression-free 
survival (PFS) or overall survival (OS) of the patients with 
mutant KRAS (23).
PIK3CA gene is frequently mutated in human cancers 
with a frequency of 32% in CRC (24). The PIK3CA 
hotspot mutations are localized in exons 9 and 20. 
Tumours with PIK3CA mutant variants were found 
to be resistant to cetuximab and panitumumab (25). 
However, the predictive role of PIK3CA mutations in 
anti-EGFR therapies remains controversial because 
PIK3CA mutations are usually found concomitantly with 
KRAS mutations (26). In this study, three PIK3CA mutant 
variants were detected. The mutant variant E545K in 
exon 9, which encodes the helical domain of PI3K 
Figure 2:  Absence of MSH6 staining in nuclei of tumour tis-
sue but with positive internal control staining of lymphocytes 
in the stroma (100x magnification)
Figure 3:  Positive staining of PMS2 in nuclei of tumour tissue 
(100x magnification)
Figure 4:  Absence of PMS2 staining in nuclei of tumour tissue 
but with positive internal control staining of lymphocytes in 
the stroma (100x magnification)
DISCUSSION
NGS-based gene panel test utilized NGS technology 
to achieve a faster and cost-effective way to investigate 
genetic alteration in cancer and assist in selecting 
relevant molecular-targeted drugs for the patient. This 
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catalytic subunit α protein, is one of the most common 
and strong oncogenic mutations in CRC. This mutant 
variant has the ability to activate PI3K signaling and 
MEK1/2 module of mitogen-activated protein kinase 
(MAPK) pathway (27). PIK3CA D1056N mutation is 
localized in exon 20, which encodes the kinase domain 
of PI3K catalytic subunit α protein. Lee et al. have shown 
that a patient with KRAS (G12D) mutant mCRC that 
also harboured PIK3CA D1056N mutation had stable 
disease for a longer period compared to other PIK3CA 
mutant variants when receiving simvastatin/cetuximab/
irinotecan treatment (28). A systematic review and 
meta-analysis also suggested that a mutation in PIK3CA 
exon 20 is a potentially better predictor biomarker 
for resistance to anti-EGFR therapy in KRAS wild-type 
mCRC (29). PIK3CA K733R mutation in exon 14 which 
was previously discovered in CRC (30) was also detected 
in this study. This mutation has been predicted to be a 
pathogenic mutation in the Cosmic Sanger database.
TP53 (tumour suppressor p53) or p53 is the most 
frequent mutated gene in the TCGA Pan-Cancer cohort 
(31). In CRC, the frequency of TP53 mutations ranges 
from 30%~45%. Mutations of TP53 are mainly observed 
at the DNA binding domain in exon 5 to exon 8 (32). 
The mutation of TP53 not only results in loss of tumour-
suppressive properties but also gain of new oncogenic 
activity. These activities include the promotion of 
cell growth, migration, invasion and metastasis, and 
chemoresistance (33). Sui and coworkers have shown 
that JNK activation promotes autophagy most probably 
via inducing Bcl-2 phosphorylation causing colon 
cancer cells to be resistant to 5-FU in-vitro (34). In this 
study, three TP53 mutations were detected, namely 
G199V (33.3%), D259Y (33.3%) and R282W (33.3%). 
The p.R282W mutant variant is a hotspot mutation that 
is localized within the DNA binding domain of the p53 
protein. This mutant variant inhibits AMPK (adenosine 
monophosphate (AMP)-activated protein kinase) 
activation, promotes invasive cell growth during tumour 
development, inhibits activity of p63 and p73, reduces 
metastasis suppressor function of Kruppel-like-factor 17 
(KLF17), promotes cellular transformation and invasion, 
and has chemoresistant properties (35)(36).  The p.G199V 
is a mutant variant that has antiapoptotic function via 
the signal transducer and activator of transcription-3 
(STAT3) pathway in KAT-18 cell line (37). The p.D259Y 
mutant variant is also localized within the DNA binding 
domain of p53 protein and has been reported in patients 
with Crohn’s disease (38). 
The BRAF gene is an important player in MAPK/ERKs 
signaling pathway affecting cell division, differentiation, 
and secretion. In CRC, the frequency of BRAF mutation 
ranged from 5%-11% (39). A systemic review revealed 
that patients with BRAF mutations have a poorer overall 
survival (OS) compared to wild-type BRAF (40). In a 
clinical study, patients with BRAF mutations receiving 
either FOLFIRI plus cetuximab or FOLFIRI has been 
associated with shorter OS (41). In this study, the most 
prevalent mutation, V600E, was detected in one sample. 
This mutant variant, localized within the activation 
segment of the kinase domain of BRAF protein, is an 
activation mutation which accounts for around 90% 
of all BRAF mutations in CRC. The V600E is also a 
predictive biomarker in the treatment of CRC patients as 
this mutant variant is resistant to BRAF inhibitors in cell 
line studies (42)(43).
Epidermal growth factor receptor (EGFR) gene, is a 
low prevalence gene mutation in CRC but in certain 
populations, the mutation frequencies can range from 
11~22% (44)(45). Although overall low in prevalence, 
chemoresistance to cetuximab was discovered in 
certain EGFR rare variants (46)(47). In this study, one 
EGFR mutation (p.G696R) was detected. To the best 
of our knowledge, this is the first time EGFR mutation 
is reported in a Malaysian CRC study. The p.G696R 
discovered is localized within the cytoplasmic domain 
of EGFR protein and was previously discovered in non-
small cell lung cancer  (48). This mutant variant has 
not been previously reported in CRC during the time of 
analysis. To the best of our knowledge, there is limited 
information on this variant. However, using different 
mutation predicting software (MutPred score=0.805, 
Provean score=-6.569, PMUT score=0.61 and PolyPen-2 
score=0.999), the score of these tests suggested this 
mutant variant to be pathogenic. 
In this study, MSH6 and PMS2 antibodies were used 
to detect the status of MMR in tumour tissue. MMR 
was considered deficient when there was a loss of 
MSH6 and/or PMS2 protein expression in the tumour 
tissue. This method was proposed by Shia et al., where 
the predictive value of IHC, using PMS2 and MSH6 
antibodies, is nearly equivalent to MSI testing (49). 
MSI/MMR has been found to be a predictive biomarker 
of treatment response to immune checkpoint inhibitors 
for colorectal carcinoma. Colorectal carcinoma patients 
with high MSI or deficient MMR was reported to response 
better to anti PD-L1 immunotherapy (pembrolizumab) 
compared to patients with low/no MSI or proficient 
MMR (12). MSI was also reported to have association 
with BRAF, TP53, PTEN, and KRAS mutations. Study by 
Albitar et al. proposed that the effectiveness of therapy 
targeting MSI and BRAF and PTEN mutation may 
increase if combined with checkpoint inhibitors (50).
There were three samples (006, 007 and 008) with a 
lower number of reads compared to other samples in 
this study. An insufficient number of reads may affect the 
detection of rare mutation with low allelic frequency. 
This was probably due to inaccurate quantification 
that affects the molarity of samples during pooling or 
the nature of the samples (FFPE tissues) that affected the 
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sequencing quality. 
 
The limitations of this study are that the sample size 
was small and the mutations detected by NGS were 
not validated by other tests. It is worthwhile to further 
examine and validate the EGFR mutant variant in a larger 
sample size with matched tumour and normal tissues to 
define whether it is a somatic or germline mutation. The 
types/sites of variant that we found in KRAS, PIK3CA, 
TP53, and BRAF often represent somatic variants. These 
somatic variants are well-known and well-characterized 
hotspot mutations.
 
CONCLUSION
We have identified mutations in KRAS codon 12 and 
13, BRAF, and PIK3CA but not NRAS and PTEN. These 
genes can predict resistance to anti-EGFR therapies in 
CRC. Three TP53 mutations were found. This is the 
first report of EGFR mutation (G696R) in Malaysia CRC 
population which is predicted to be a pathogenic variant. 
More samples need to be tested to further support these 
findings. This study has provided information on the 
potential clinical utility of this 7-cancer gene panel and 
is also useful for designing new gene panels with an 
increased number of genes for future mutation testing.
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